National Institute for the Infectious Diseases “L. Spallanzani”, IRCCS. Recommendations for COVID-19 Clinical Management

Título

National Institute for the Infectious Diseases “L. Spallanzani”, IRCCS. Recommendations for COVID-19 Clinical Management

Autor

E. Nicastri, N. Petrosillo, L. Lepore, A. Mondi, T. Ascoli Marchetti, D’Offizi G., F. Palmieri, L. Marchioni, S. Murachelli, G. Ippolito, A. Antinori, INMI COVID-19 Treatment Group (ICOTREG)

Descripción

On January 9 2020, the “World Health Organization” (WHO) declared the identification, by Chinese Health authorities, of a novel coronavirus, further classified as SARS-CoV-2 responsible of a diseases (COVID-19) ranging from asymptomatic cases to severe respiratory involvement. On March 9 2020, WHO declared COVID-19 a global pandemic. Italy is the second most affected country by COVID-19 infection after China. The “L. Spallanzani” National Institute for the Infectious Diseases, IRCCS has been the first Italian hospital to admit and manage patients affected by COVID-19. Hereby, we show our recommendations for the management of COVID-19 patients, based on very limited clinical evidences; these recomendations should be considered as expert opinions, which may be modified according to newly produced literature data.

Fecha

2020

Materia

COVID-19, SARS-CoV-2, treatment

Identificador

DOI: 10.4081/idr.2020.8543

Fuente

Infectious Disease Reports

Editor

PAGEPress Publications

Cobertura

Other systems of medicine

Idioma

EN

Archivos

https://socictopen.socict.org/files/to_import/pdfs/article 1480.pdf

Colección

Citación

E. Nicastri, N. Petrosillo, L. Lepore, A. Mondi, T. Ascoli Marchetti, D’Offizi G., F. Palmieri, L. Marchioni, S. Murachelli, G. Ippolito, A. Antinori, INMI COVID-19 Treatment Group (ICOTREG), “National Institute for the Infectious Diseases “L. Spallanzani”, IRCCS. Recommendations for COVID-19 Clinical Management,” SOCICT Open, consulta 18 de abril de 2026, https://www.socictopen.socict.org/items/show/1437.

Formatos de Salida

Position: 15133 (20 views)